Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
CIA-Linked Investor Helped Quantum Systems Expand in US 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Street Poller Media and The Boom of the Street Interview Ad Industry 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
OpenAI Rejects Apple Trade Secret Theft Claims 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
France Targets Shein, Temu With Fast-Fashion Fees 
Add as a preferred source on Google
Merck & Co Inc is buying Pandion Therapeutics, the biotechnology company developing bispecific antibody therapeutics headquartered in Massachusetts. It was said that the pharmaceutical firm is shelling out a total of $1.85 billion in cash to acquire it.
Merck’s target expansion
The acquisition was revealed on Feb. 25 through a joint statement from Merck and Pandion Therapeutics. The deal is also equivalent to a $60 per share deal that amounts to a 134% premium to Pandion’s closing price on Wednesday.
As per Fox Business, Merck & Co Inc. is purchasing the said drug developer to broaden its portfolio of drugs designed for autoimmune diseases. With the deal, the pharmaceutical company that is one of the largest in the world is also set to have Pandion’s major drug candidate called PT101, which is currently undergoing testing for public release.
The drug already completed and passed the phase 1a clinical trial last month for safety and tolerability. It is now in the early stage of the trial involving volunteer patients with autoimmune diseases.
“This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational characteristics,” Dr. Dean Y. Li, Merck Research Laboratories president said in a press release. “Pandion has applied its TALON technology to develop a robust pipeline of candidates designed to re-balance the immune response with potential applications across a wide array of autoimmune diseases.”
Merck and Pandion are expected to close the deal before the second half of this year begins. Both companies confirmed this during the announcement this week.
Merck and Pandion’s stocks up after the buyout reveal
The New Jersey-headquartered pharma company is paying more than double Pandion’s current stock price, and the news of this deal drove both Merck and Pandion’s share to shoot up.
Shares of the drug developer closed at $25.63 after the confirmation of the acquisition, while Merck shares increased by 0.3% in premarket trading.
Meanwhile, this was Merck’s latest purchase as it had entered into a number of deals before 2020 closed. One of its major acquisitions was the biotech company VelosBio which was bought for $2.75 billion. It also acquired Oncolmmune, another private firm, for $425 million.
